Full-Time

Research Associate III/Sr. Research Associate

Posted on 7/30/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$105k - $115kAnnually

+ Performance Bonus + Equity + Health Benefits

Mid

San Bruno, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • BS/MS in a biology-related discipline
  • BS and >3 years, or MS and >2 year hands-on experience in a cell/molecular biology laboratory (oncology setting highly preferred)
  • Experience with oncology in vivo models: xenografts and syngeneic, tumor measurements, ex-vivo pharmacodynamics
  • Experience with mammalian cell culture, test article formulation, protein expression quantification (ELISA, MSD), qPCR, and western blot/immunoprecipitation
  • Experience with analyzing and presenting study results
  • Strong written and oral communication skills
Responsibilities
  • Execution of in vivo (tumor cell inoculations, dosing (po, sc, ip, iv), and blood sampling) and ex vivo pharmacology experiments (target and mechanism engagement) to assess the inhibition or activation of novel targets in the oncology setting
  • Assist in the planning and design of model development, PK/PD, tolerability, and efficacy studies using mostly (but not limited to) small molecule therapeutics
  • Graph, interpret, and communicate experimental data
  • Maintain records in written and electronic laboratory notebooks
  • Manage lab inventory and equipment
  • Understand and implement applicable regulations around animal care/safety/handling

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

INACTIVE